Notably, ARID1A mutations, frequently observed in gastric cancer and particularly enriched in the TCGA genomically stable and Epstein–Barr virus (EBV)-positive subtypes, have been linked to altered chromatin remodeling, impaired DNA repair, and increased RS, molecular hallmarks that may confer heightened vulnerability to ATR blockade. This evidence concerns the gene ARID1A and gastric cancer.